Literature DB >> 8867261

The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomic responses to corneal stimulation in the rat.

David A Bereiter1, Dominique F Bereiter, Charles B Hathaway.   

Abstract

The N-methyl-D-aspartate (NMDA) receptor is implicated in multiple aspects of pain processing by the central nervous system. However, the role of NMDA receptors in the endocrine and autonomic aspects of nociception remains uncertain. The present study examined the influence of the NMDA receptor antagonist, MK-801 (0.02-2.0 mg/kg, intracarotid), on the adrenal and autonomic responses to corneal stimulation (mustard oil, 20% sol.) in barbiturate-anesthetized rats. Fos-like immunoreactivity (Fos-LI) evoked by corneal stimulation was quantified within the spinal trigeminal nucleus (Vsp) of MK-801 pretreated animals to assess activation of central trigeminal neurons. Corneal stimulation-evoked increases in the plasma concentrations of adrenocorticotropin (ACTH), epinephrine and norepinephrine were reduced dose-dependently by MK-801. Plasma ACTH also increased after moderate hemorrhage, a response that was not affected by MK-801. MK-801 did not reduce the magnitude of corneal stimulation-evoked increases in arterial pressure and heart rate; however, prestimulus arterial pressure was reduced by drug treatment. Fos-LI was distributed bimodally within the ipsilateral caudal Vsp: one peak of Fos-LI in the subnucleus interpolaris/caudalis transition region and a second peak within the superficial laminae of the subnucleus caudalis/upper cervical cord transition region. The magnitude of both peaks of Fos-LI was reduced dose-dependently by MK-801. These results indicate a significant contribution from NMDA receptors in control of select endocrine and autonomic responses that accompany trigeminal nociception and in activation of central trigeminal neurons that process corneal nociceptive input.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867261     DOI: 10.1016/0304-3959(95)00095-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  11 in total

1.  Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis.

Authors:  D D Mitsikostas; M Sanchez del Rio; C Waeber; Z Huang; F M Cutrer; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 2.  The role of trigeminal interpolaris-caudalis transition zone in persistent orofacial pain.

Authors:  Ke Ren; Ronald Dubner
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

Review 3.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 4.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

5.  In vivo patch-clamp analysis of response properties of rat primary somatosensory cortical neurons responding to noxious stimulation of the facial skin.

Authors:  Mamoru Takeda; Masayuki Takahashi; Masanori Nasu; Shigeji Matsumoto
Journal:  Mol Pain       Date:  2010-05-26       Impact factor: 3.395

6.  Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.

Authors:  Robin James Storer; Simon Akerman; Peter J Goadsby
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

7.  A trigeminoreticular pathway: implications in pain.

Authors:  W Michael Panneton; Qi Gan; Robert S Livergood
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

Review 8.  Mechanisms of Peripheral and Central Pain Sensitization: Focus on Ocular Pain.

Authors:  Giulia Puja; Balazs Sonkodi; Rita Bardoni
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

Review 9.  The Role of Metabolism in Migraine Pathophysiology and Susceptibility.

Authors:  Olivia Grech; Susan P Mollan; Benjamin R Wakerley; Daniel Fulton; Gareth G Lavery; Alexandra J Sinclair
Journal:  Life (Basel)       Date:  2021-05-01

10.  Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Jakob Møller Hansen; Dalia Abou-Kassem; Anna Koldbro Hansted; Kumari Ubhayasekera; Jonas Bergquist; László Vécsei; Inger Jansen-Olesen; Messoud Ashina
Journal:  Pharmacol Res Perspect       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.